Rice Hall James & Associates LLC increased its stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 4.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 948,281 shares of the company's stock after purchasing an additional 43,381 shares during the period. Rice Hall James & Associates LLC owned approximately 1.50% of Evolus worth $10,469,000 as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. KBC Group NV bought a new position in shares of Evolus in the fourth quarter worth approximately $49,000. Point72 Asset Management L.P. bought a new position in shares of Evolus in the third quarter worth approximately $132,000. China Universal Asset Management Co. Ltd. increased its position in shares of Evolus by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company's stock worth $148,000 after purchasing an additional 1,291 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Evolus in the third quarter worth approximately $191,000. Finally, Oppenheimer & Co. Inc. purchased a new stake in Evolus in the third quarter worth approximately $212,000. 90.69% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several analysts have issued reports on EOLS shares. HC Wainwright reaffirmed a "buy" rating and issued a $27.00 target price on shares of Evolus in a research note on Friday, February 14th. Barclays increased their price objective on Evolus from $20.00 to $22.00 and gave the company an "overweight" rating in a research note on Monday, January 27th. Finally, Needham & Company LLC reissued a "buy" rating and set a $22.00 price objective on shares of Evolus in a research note on Tuesday, January 21st.
Read Our Latest Stock Report on EOLS
Evolus Trading Down 4.3 %
Shares of NASDAQ:EOLS traded down $0.63 during trading on Friday, reaching $13.99. 585,594 shares of the company traded hands, compared to its average volume of 893,250. The firm has a market capitalization of $885.85 million, a price-to-earnings ratio of -15.37 and a beta of 1.33. Evolus, Inc. has a 52-week low of $9.25 and a 52-week high of $17.82. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The business's fifty day moving average is $12.35 and its 200-day moving average is $14.03.
Evolus Profile
(
Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
See Also
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
